secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001232524-24-000084
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Q3 revenue tops $1.05B, raises EPS guidance, affirms 2024 revenue outlook at $4.0-4.1B
--------------------------------------------------------------------------------

- Q3 2024 record revenue >$1.05B; key growth drivers (Xywav, Epidiolex, Rylaze) up 14% YoY.
- Total 2024 revenue guidance reaffirmed at $4.0-4.1B; oncology revenue guidance lowered to $1.08-1.13B.
- GAAP EPS guidance raised to $6.70-8.50; non-GAAP EPS guidance raised to $19.50-20.60.
- Xywav added ~400 net patients in Q3; strong sleep performance continues.
- Zanidatamab PDUFA Nov 29 for 2L BTC; sNDA for Zepzelca in 1L ES-SCLC planned 1H25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252424000084/0001232524-24-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252424000084/jazz-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001232524-24-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer